

HCS Pharma awarded at BIO ASIA Taiwan 2021 for its proprietary BIOMIMESYS® technology

Lille, France – 12/10/2021 : **The biotech startup, HCS Pharma, has been awarded by the prestigious NHRI (National Health Research Institute) of Taiwan during BIO ASIA Taiwan 2021.**



Following HCS Pharma's entry into the NHRI incubator (Taiwan) in August 2021 to develop cell therapy tools using the proprietary BIOMIMESYS® technology, the startup was invited to present its products at BIO Asia-Taiwan in November 2021. At this occasion BIOMIMESYS® technology was awarded the "Key Startups Company (關鍵新創) - Partnering and Medical Innovation (攜手同行暨創醫獎)" award. This distinction granted by the NHRI and the TTIC (Technology Transfer & Incubation Center) reinforces the worldwide recognition of BIOMIMESYS® and HCS Pharma, already



recognized as "Deep Tech Pioneers" by the 2020 Hello Tomorrow challenge and ranked in the "Top43" deeptech companies coached in 2020 by the European Invest Horizon program.

This award strengthens HCS Pharma's presence in Taiwan by accelerating the growth of its representative office (headed by Joseph Chou, currently CEO of Tokyo Futur Style Taiwan) and the plans to deploy a local production facility for BIOMIMESYS®.

BIOMIMESYS®

After several years of research, HCS Pharma has brought to the drug discovery market its unique BIOMIMESYS® technology, which allows for the simple implementation of 3D in vitro tests in conditions close to those of the human body organs. In vitro tests are a critical step in the development of new drugs. They allow the validation of a molecule's efficacy and safety well before the costly phases of clinical testing. However, these tests are still often carried out with 2D cell culture systems, which are not close enough to the human body to give predictive results. The transition to 3D cell culture tools is an obligation for research and industry. BIOMIMESYS® technology facilitates this transition by using natural compounds, as close as possible to biological reality. BIOMIMESYS® technology is protected by an exclusive patent held by HCS Pharma.

HCS Pharma

HCS Pharma is a biotech start-up located in Lille that develops and markets 3D cell culture products based on its proprietary BIOMIMESYS® technology and develops its own 3D cell models alone or in partnership that it offers to their customers from pharmaceutical, dermo-cosmetic and food industries. HCS pharma team has unique expertise in the development of new 3D in vitro models and their miniaturization and automation to perform high throughput screening in order to analyze efficacy or safety effects of a large number of products. BIOMIMESYS® is a groundbreaking 3D technology that enables the faithful reproduction of the microenvironment, also called Extra-Cellular Matrix (ECM) of any organ/tissue, healthy or cancerous. It is also the only ready-to-use organ-specific 3D technology usable in medium/high throughput screening of molecules using cellular imaging technology called High Content Screening (HCS).

Contact

Nathalie MAUBON / CEO / nathalie.maubon@hcs-pharma.com / +33 (0)769 999 137